Project Grant R01CA292427
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$645K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $701,890.00 to the University of Illinois to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The key research aims are to: 1) define how sunitinib translationally regulates the protein SND1, 2) elucidate the role of SND1 in mediating endothelial tolerance against sunitinib's...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $123,409 to Northwestern University to investigate the role of Gasdermin D in the bone marrow microenvironment during the progression of clonal hematopoiesis, a pre-malignant condition. The project aims to uncover the cellular and molecular mechanisms by which Gasdermin D deficiency in non-hematopoietic stromal cells mitigates the progression of clonal hematopoiesis. Key activities...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This Project Grant award, titled "Optical Hyperspectral Nanoscale Chromatin Analysis for Colon Cancer Risk-Stratification", is funded by the National Cancer Institute (NCI) under CFDA 93.394 Cancer Detection and Diagnosis Research program. The $670,534 award to Northwestern University aims to develop a screening test to identify patients who harbor advanced adenomas and would benefit from colonoscopy, a crucial step in preventing colorectal cancer, the second leading cause of cancer...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
This Project Grant award of $696,133, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to develop non-invasive imaging methodologies for tracking neural stem cells (NSCs) in the brains of mouse models bearing breast cancer brain metastases. The primary awardee, Northwestern University, will optimize an integrated single-photon emission microscope and magnetic resonance imaging system to enable high-resolution,...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $160,642 to Weill Medical College of Cornell University to characterize the role of oncogenic NRAS mutations in acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH) mutations. The project aims to understand how NRAS mutations impact the biology and therapeutic response of IDH-mutant AML, with a focus on evaluating the mechanism by which NRAS mitigates the differentiation...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...